Clinical Trial Update: The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the impact of ezetimibe on biochemical markers of cardiovascular risk in kidney transplant recipients with dyslipidemia; study complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Kidney Transplantation

Drugs mentioned

• EZETIMIBE (EZETIMIBE)

Snippet

Sponsor: University Medical Centre Ljubljana | Conditions: Dyslipidemia, Transplants | Phase 4 | Status: COMPLETED